Sort   by:  
 Page size 
ProteomicsKinome profiling: cabozantinib treatment in a mouse model of plexiform neurofibroma
Neurofibromatosis type 1 (NF1) is the most common autosomal dominant disorder, affecting 1 in 3,500 individuals worldwide and predisposing to cancer. Germline mutations in the NF1 gene, encoding the p21Ras GTPase-activating protein (GAP) neurofibromin, are the underlying cause for NF1. Somatic inact...
ORGANISM(S): Mus musculus (Mouse) 
2020-11-19 | PXD019138 | Pride
Receptor tyrosine kinase Nf1 Xl184 
ProteomicsComputational and Experimental Verification of Cabozantinib to Inhibit DNA Damage Repair in Liver Cancer
The proteomics study of cabozantinib-treated hepatocellular carcinoma cells.
ORGANISM(S): Homo Sapiens 
2025-11-13 | PXD070703 |
ProteomicsKinome profiling: cabozantinib treatment in a mouse model of plexiform neurofibroma
Neurofibromatosis type 1 (NF1) is the most common autosomal dominant disorder, affecting 1 in 3,500 individuals worldwide and predisposing to cancer. Germline mutations in the NF1 gene, encoding the p21Ras GTPase-activating protein (GAP) neurofibromin, are the underlying cause for NF1. Somatic inact...
ORGANISM(S): Mus musculus (Mouse) 
2023-05-18 | PXD019005 | Pride
Receptor tyrosine kinase Nf1 Xl184 
GenomicsTranscriptomic differences in cabozantinib-resisant AML cells.
Transcriptomic differences in cabozantinib-resisant AML cells.
PRJNA982820 | ENA
ProteomicsQuantitative Phosphoproteomics for Prolonged Cabozantinib-Treated Renal Cell Carcinoma Cells
Patients with recurrent or metastatic renal cell carcinoma (mRCC) usually develop resistance to targeted tyrosine kinase inhibitors (TKI). Recently, FDA-approved cabozantinib is found to inhibit pathways linked to TKI resistance. Although cabozantinib is believed to be a new gold standard in managin...
ORGANISM(S): Homo sapiens (Human) 
2026-03-03 | PXD022957 | Pride
Human Renal cell carcinoma Cabozantinib 
TranscriptomicsTranscriptomic differences in cabozantinib-resisant AML cells.
Cabozantinib is a type II tyrosine kinase inhibitor (TKI), which is approved by FDA for treating several solid tumors including advanced/progressive metastatic medullar thyroid cancer, advanced renal cell carcinoma, and advanced and progressive hepatocellular carcinoma. Moreover, we and others revea...
ORGANISM(S): Homo sapiens 
2026-02-25 | GSE234724 | GEO
TranscriptomicsPotent antitumor activity of Cabozantinib, a c-MET and VEGFR2 Inhibitor, in a Colorectal Cancer Patient-derived Tumor Explant Model
Anti-angiogenic therapy is commonly used for the treatment of CRC. Although patients derive some clinical benefit, treatment resistance inevitably occurs. The MET signaling pathway has been proposed to be a major contributor of resistance to anti-angiogenic therapy. MET is upregulated in response to...
ORGANISM(S): Homo sapiens 
2014-08-30 | E-GEOD-60939 | biostudies-arrayexpress
ProteomicsDivergent polypharmacology-driven cellular activity of structurally similar multi-kinase inhibitors through cumulative differential effects on individual targets: Drug Pulldowns
Despite recent successes of precision and immunotherapies there is a persisting need for novel targeted or multi-targeted approaches in complex diseases. Through a systems pharmacology approach including phenotypic screening, chemical and phosphoproteomics and RNA-Seq, we elucidated the targets and ...
ORGANISM(S): Homo sapiens (Human) 
2019-06-24 | PXD012961 | Pride
Cabozantinib Chemical proteomics Polypharmacology Foretinib Lung cancer 
GenomicsCabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression
Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression
PRJNA1080586 | ENA
GenomicsEffect of cabozantinib on transcriptome and signaling pathways in leukemic cell line Kasumi-1
Effect of cabozantinib on transcriptome and signaling pathways in leukemic cell line Kasumi-1
PRJNA644355 | ENA
Sort   by:  
 Page size